Nanoscale Drug Delivery Systems in Glioblastoma

Liu, Zihao; Ji, Xiaoshuai; Dong, He; Zhang, Rui; Liu, Qian; Xin, Tao

doi:10.1186/s11671-022-03668-6

Cited by 36 publications

(37 citation statements)

References 212 publications

(169 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the passive route, extensive blood vessels caused by tumor-induced angiogenesis and defects in lymphatic drainage could extend the release and sustain of nano drugs in the tumor site. On the other hand, active targeting uses bio-mimetic agents like CM vesicles for more effective delivery ( Liu et al, 2022a ). The mechanism by which CM-coated NPs could penetrate BBB varied according to the NP type and carried drug and, as mentioned, can be generally classified into passive and active routes ( Bhaskar et al, 2010 ).…”

Section: An Overview On Nps In Gbm Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Allami

Heidari²,

Rezaei³

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Glioblastoma multiform (GBM) is the most prevalent and deadliest primary brain malignancy in adults, whose median survival rate does not exceed 15 months after diagnosis. The conventional treatment of GBM, including maximal safe surgery followed by chemotherapy and radiotherapy, usually cannot lead to notable improvements in the disease prognosis and the tumor always recurs. Many GBM characteristics make its treatment challenging. The most important ones are the impermeability of the blood-brain barrier (BBB), preventing chemotherapeutic drugs from reaching in adequate amounts to the tumor site, intratumoral heterogeneity, and roles of glioblastoma stem cells (GSCs). To overcome these barriers, the recently-developed drug-carrying approach using nanoparticles (NPs) may play a significant role. NPs are tiny particles, usually less than 100 nm showing various diagnostic and therapeutic medical applications. In this regard, cell membrane (CM)-coated NPs demonstrated several promising effects in GBM in pre-clinical studies. They benefit from fewer adverse effects due to their specific targeting of tumor cells, biocompatibility because of their CM surfaces, prolonged half-life, easy penetrating of the BBB, and escaping from the immune reaction, making them an attractive option for GBM treatment. To date, CM-coated NPs have been applied to enhance the effectiveness of major therapeutic approaches in GBM treatment, including chemotherapy, immunotherapy, gene therapy, and photo-based therapies. Despite the promising results in pre-clinical studies regarding the effectiveness of CM-coated NPs in GBM, significant barriers like high expenses, complex preparation processes, and unknown long-term effects still hinder its mass production for the clinic. In this regard, the current study aims to provide an overview of different characteristics of CM-coated NPs and comprehensively investigate their application as a novel treatment approach in GBM.

show abstract

Section: An Overview On Nps In Gbm Treatmentmentioning

confidence: 99%

“…Another approach to reducing NPs toxicity is to apply a targeted delivery system. Targeted delivery can be achieved with synthetic polymers like PEG or biomimetic membrane components ( Chai et al, 2017 ; Raza et al, 2021 ; Liu et al, 2022a ).…”

Section: An Overview On Cm-coating Technologymentioning

confidence: 99%

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Allami

Heidari²,

Rezaei³

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Nanomedicine, the interdisciplinary science focusing on the medical application of nanotechnology, has made remarkable advances in cerebral disorders therapy. Compared to conventional medication administration route, it is well acknowledged that nanomedicine has the advantages including reduced circulatory clearance, prolonged half-time, sustained drug release and minimized side effects [ 15 ]. Currently, a vast variety of nanoparticles have been exploited in IS therapy, including inorganic nanomaterials, organic nanomaterials, metallic nanomaterials and synthetic nanomaterials.…”

Section: Introductionmentioning

confidence: 99%

Biomimetic nanoparticles in ischemic stroke therapy

Liu

Xiao

et al. 2023

Discover Nano

Self Cite

View full text Add to dashboard Cite

Ischemic stroke is one of the most severe neurological disorders with limited therapeutic strategies. The utilization of nanoparticle drug delivery systems is a burgeoning field and has been widely investigated. Among these, biomimetic drug delivery systems composed of biogenic membrane components and synthetic nanoparticles have been extensively highlighted in recent years. Biomimetic membrane camouflage presents an effective strategy to prolong circulation, reduce immunogenicity and enhance targeting. For one thing, biomimetic nanoparticles reserve the physical and chemical properties of intrinsic nanoparticle. For another, the biological functions of original source cells are completely inherited. Compared to conventional surface modification methods, this approach is more convenient and biocompatible. In this review, membrane-based nanoparticles derived from different donor cells were exemplified. The prospect of future biomimetic nanoparticles in ischemic stroke therapy was discussed. Graphic abstract

show abstract

“…Approximately 88% of patients with GBM have a 5-years survival rate of <5%, and the overall median survival time is only around 14 months ( Tykocki and Eltayeb 2018 ). The main treatment strategy also has a number of disadvantages ( Martínez Bedoya et al, 2021 ; Liu Z. et al, 2022 ). For example, due to the complexity of, and dynamic changes in, the tumor microenvironment, patients frequently exhibit resistance to chemotherapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma

Shao

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Gliomas are the most common and fatal malignant type of tumor of the central nervous system. RNA post-transcriptional modifications, as a frontier and hotspot in the field of epigenetics, have attracted increased attention in recent years. Among such modifications, methylation is most abundant, and encompasses N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1 methyladenosine (m1A), and 7-methylguanosine (m7G) methylation.Methods: RNA-sequencing data from healthy tissue and low-grade glioma samples were downloaded from of The Cancer Genome Atlas database along with clinical information and mutation data from glioblastoma tumor samples. Forty-nine m6A/m5C/m1A/m7G-related genes were identified and an m6A/m5C/m1A/m7G-lncRNA signature of co-expressed long non-coding RNAs selected. Least absolute shrinkage and selection operator Cox regression analysis was used to identify 12 m6A/m5C/m1A/m7G-related lncRNAs associated with the prognostic characteristics of glioma and their correlation with immune function and drug sensitivity analyzed. Furthermore, the Chinese Glioma Genome Atlas dataset was used for model validation.Results: A total of 12 m6A/m5C/m1A/m7G-related genes (AL080276.2, AC092111.1, SOX21-AS1, DNAJC9-AS1, AC025171.1, AL356019.2, AC017104.1, AC099850.3, UNC5B-AS1, AC006064.2, AC010319.4, and AC016822.1) were used to construct a survival and prognosis model, which had good independent prediction ability for patients with glioma. Patients were divided into low and high m6A/m5C/m1A/m7G-LS groups, the latter of which had poor prognosis. In addition, the m6A/m5C/m1A/m7G-LS enabled improved interpretation of the results of enrichment analysis, as well as informing immunotherapy response and drug sensitivity of patients with glioma in different subgroups.Conclusion: In this study we constructed an m6A/m5C/m1A/m7G-LS and established a nomogram model, which can accurately predict the prognosis of patients with glioma and provides direction toward promising immunotherapy strategies for the future.

show abstract

Nanoscale Drug Delivery Systems in Glioblastoma

Cited by 36 publications

References 212 publications

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Biomimetic nanoparticles in ischemic stroke therapy

An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma

Contact Info

Product

Resources

About